Privia Health Group (PRVA) just released its fourth quarter and full year 2025 results, reporting higher sales and net income, and paired the update with 2026 GAAP revenue guidance in the US$2.35b to US$2.45b range.

The earnings and revenue guidance appear to have shifted sentiment in the short term, with a 1 day share price return of 5.20% taking Privia Health Group to US$22.65. However, the 1 year total shareholder return of 11.04% and 3 year total shareholder return of 19.42% indicate comparatively weaker momentum over a longer horizon.

If this update has you reassessing healthcare opportunities, it could be worth scanning our list of 30 healthcare AI stocks as a starting point for other ideas in the space.

With earnings, guidance and a recent share price bounce all on the table, the key question now is whether Privia Health Group at US$22.65 still trades at a discount, or if the market is already pricing in future growth.

Most Popular Narrative: 27.5% Undervalued

Privia Health Group’s most followed narrative pegs fair value at $31.25 versus the latest close at $22.65, framing the current price as a sizable discount that rests on detailed growth and margin assumptions.

Demographic tailwinds from the growing and aging U.S. population are driving sustained increases in patient volumes across Privia's network, which supports strong top-line revenue growth and predictable, recurring fee streams for the company's tech and services platform. The industry-wide movement towards value-based care, with associated shared savings and care management fees, is enabling Privia to grow its value-based attributed lives at a double-digit rate and to expand margins as risk-sharing agreements mature, positively impacting earnings and long-term EBITDA growth.

Curious what kind of revenue trajectory, margin build and future earnings power need to line up for that $31.25 figure to hold? The narrative leans on multi year compounding growth, rising profitability and a premium earnings multiple that would usually be reserved for faster growing names. Want to see exactly how those moving parts fit together and what assumptions sit behind that discounted cash flow using a 6.978% rate? The full write up lays out the step by step logic behind that fair value call.

Result: Fair Value of $31.25 (UNDERVALUED)

However, you still need to weigh the risk that insurer and hospital consolidation could weaken physician bargaining power, while higher labor costs may pressure margins and growth plans.

Next Steps

If this appears to be a bullish story with some important unknowns, it may be worth reviewing the data yourself and acting promptly to form your own view, starting with 4 key rewards.

Looking for more investment ideas?

If you stop at just one stock story, you miss the chance to compare, pressure test your thinking, and spot ideas that might fit your goals even better.

• Spot potential mispricings early by scanning our list of 53 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect them yet.
• Strengthen the defensive side of your portfolio by checking companies in our solid balance sheet and fundamentals stocks screener (41 results) that focus on liquidity and manageable debt.
• Put your cash to work with income ideas by reviewing our curated 15 dividend fortresses that focus on higher yields with supporting fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.